J Drugs Dermatol. 2021 Jan 1;20(1):115-114. doi: 10.36849/JDD.5628.
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. In Dermatology, focus on the continued safe usage of immunomodulating biologic therapies has attracted particular interest as the COVID-19 virus represents a novel infection risk. While guidance on biologic initiation and continuation has been established,1 the return to normalcy will likely involve a safe and effective vaccine. This vaccine(s) will represent a new clinical hurdle for prescribers who have continued patients on biologic therapy throughout the pandemic.
COVID-19 大流行迫使所有专业的医疗保健提供者调整其临床实践方法。在皮肤科，由于 COVID-19 病毒代表了一种新的感染风险，因此持续关注免疫调节生物疗法的安全使用特别受到关注。虽然已经制定了生物制剂起始和维持治疗的指南，1 但恢复常态可能需要安全有效的疫苗。对于在大流行期间继续为患者使用生物制剂治疗的医生来说，这种疫苗将代表一个新的临床难题。
